Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters.

Autor:	Lasrado N; Beth Israel Deaconess Medical Center, Boston, MA, USA., Collier AY; Beth Israel Deaconess Medical Center, Boston, MA, USA., Miller J; Beth Israel Deaconess Medical Center, Boston, MA, USA., Hachmann NP; Beth Israel Deaconess Medical Center, Boston, MA, USA., Liu J; Beth Israel Deaconess Medical Center, Boston, MA, USA., Sciacca M; Beth Israel Deaconess Medical Center, Boston, MA, USA., Wu C; Beth Israel Deaconess Medical Center, Boston, MA, USA., Anand T; Beth Israel Deaconess Medical Center, Boston, MA, USA., Bondzie EA; Beth Israel Deaconess Medical Center, Boston, MA, USA., Fisher JL; Beth Israel Deaconess Medical Center, Boston, MA, USA., Mazurek CR; Beth Israel Deaconess Medical Center, Boston, MA, USA., Patio RC; Beth Israel Deaconess Medical Center, Boston, MA, USA., Powers O; Beth Israel Deaconess Medical Center, Boston, MA, USA., Rodrigues SL; Beth Israel Deaconess Medical Center, Boston, MA, USA., Rowe M; Beth Israel Deaconess Medical Center, Boston, MA, USA., Surve N; Beth Israel Deaconess Medical Center, Boston, MA, USA., Ty DM; Beth Israel Deaconess Medical Center, Boston, MA, USA., Korber B; Los Alamos National Laboratory, Los Alamos, New Mexico, USA., Barouch DH; Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2023 Jan 23. Date of Electronic Publication: 2023 Jan 23.
DOI:	10.1101/2023.01.22.525079
Abstrakt:	The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 includes the G252V and F486P mutations. XBB.1.5 has rapidly increased in frequency and has become the dominant virus in New England. The bivalent mRNA vaccine boosters have been shown to increase neutralizing antibody (NAb) titers to multiple variants, but the durability of these responses remains to be determined. We assessed humoral and cellular immune responses in 30 participants who received the bivalent mRNA boosters and performed assays at baseline prior to boosting, at week 3 after boosting, and at month 3 after boosting. Our data demonstrate that XBB.1.5 substantially escapes NAb responses but not T cell responses after bivalent mRNA boosting. NAb titers to XBB.1 and XBB.1.5 were similar, suggesting that the F486P mutation confers greater transmissibility but not increased immune escape. By month 3, NAb titers to XBB.1 and XBB.1.5 declined essentially to baseline levels prior to boosting, while NAb titers to other variants declined less strikingly. Competing Interests: Conflicts of Interest The authors report no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu